Kairos Pharma Ltd
NYSE American:KAPA

  • LAST PRICE
    2.0555
  • TODAY'S CHANGE (%)
    -0.1545 (-6.9910%)
  • Bid / Lots
    2.0600/ 2
  • Ask / Lots
    2.1000/ 1
  • Open / Previous Close
    2.1200 / 2.2100
  • Day Range
    1.8800
    2.3300
  • 52 Week Range
    1.2200
    4.0000
  • Volume
    708,292

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Recent News

0 New Today

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
KAPA
Kairos Pharma Ltd
28.4M
-13.2x
---
ATHA
Athira Pharma Inc
28.1M
-0.3x
---
CVKD
Cadrenal Therapeutics Inc
27.5M
-2.8x
---
AEON
Aeon Biopharma Inc
27.3M
-0.1x
---
AKTX
Akari Therapeutics PLC
27.2M
-0.7x
---
ACXP
Acurx Pharmaceuticals Inc
29.6M
-1.5x
---
As of 2024-11-15

Company Information

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its products consist of five pre-clinical or clinical-trial stage drug candidates developed by it and designed to target immune response, and two therapeutic agents developed by its Enviro Therapeutics, Inc. (Enviro) subsidiary and designed to increase anti-tumor response in conjunction with cancer therapies by addressing resistance to these agents. Its product portfolio includes a variety of technologies licensed by its Enviro subsidiary and consists of compositions and methods for treating diseases and conditions by targeting CD105 and depleting mitochondrial DNA from the circulation. Its products include KROS 101, 102, 201, 301, 401, ENV 105 and 205.

Contact Information

Headquarters
2355 Westwood Blvd. #139LOS ANGELES, CA, United States 90064
Phone
818-404-5541
Fax
845-818-3588

Executives

Chairman of the Board, Chief Executive Officer
John Yu
Chief Financial Officer
Douglas Samuelson
Chief Scientific Officer
Neil Bhowmick
Vice President - Research & Development
Ramachandran Murali
Independent Director
Hyun Bae

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$26.4M
Revenue (TTM)
$0.00
Shares Outstanding
12.8M
Kairos Pharma Ltd does not pay a dividend.
Beta
---
EPS
$-0.16
Book Value
$-0.16
P/E Ratio
-13.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.